TG Therapeutics Stock Forecast, Price & News

TG Therapeutics (NASDAQ:TGTX) Frequently Asked Questions

Is TG Therapeutics a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TG Therapeutics in the last year. There are currently 1 sell rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TG Therapeutics stock.
View analyst ratings for TG Therapeutics or view top-rated stocks.

How has TG Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

TG Therapeutics' stock was trading at $10.01 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, TGTX stock has increased by 56.2% and is now trading at $15.64.
View which stocks have been most impacted by COVID-19.

When is TG Therapeutics' next earnings date?

TG Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, March 1st 2022.
View our earnings forecast for TG Therapeutics.

How were TG Therapeutics' earnings last quarter?

TG Therapeutics, Inc. (NASDAQ:TGTX) issued its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.56) by $0.09. The biopharmaceutical company had revenue of $2.03 million for the quarter, compared to analysts' expectations of $3.23 million. TG Therapeutics had a negative net margin of 7,784.36% and a negative trailing twelve-month return on equity of 82.68%. During the same quarter in the prior year, the firm earned ($0.73) earnings per share.
View TG Therapeutics' earnings history.

What price target have analysts set for TGTX?

4 Wall Street analysts have issued twelve-month target prices for TG Therapeutics' shares. Their forecasts range from $13.00 to $95.00. On average, they expect TG Therapeutics' share price to reach $54.75 in the next year. This suggests a possible upside of 250.1% from the stock's current price.
View analysts' price targets for TG Therapeutics or view top-rated stocks among Wall Street analysts.

Who are TG Therapeutics' key executives?

TG Therapeutics' management team includes the following people:

• Michael Sean Weiss, Chairman, President & Chief Executive Officer
• Sean A. Power, Chief Financial Officer, Secretary & Treasurer
• Owen A. O'Connor, Chief Scientific Officer
• Adam Waldman, Chief Commercial Officer
• Jenna A. Bosco, Senior Vice President-Corporate Communications

Who are some of TG Therapeutics' key competitors?

Some companies that are related to TG Therapeutics include Bausch Health Companies (BHC), United Therapeutics (UTHR), CureVac (CVAC), Ascendis Pharma A/S (ASND), Evotec (EVTCY), Jazz Pharmaceuticals (JAZZ), Biohaven Pharmaceutical (BHVN), Grifols (GRFS), Arrowhead Pharmaceuticals (ARWR), Mirati Therapeutics (MRTX), Sarepta Therapeutics (SRPT), Legend Biotech (LEGN), Zai Lab (ZLAB), BridgeBio Pharma (BBIO) and Blueprint Medicines (BPMC).
View all of TGTX's competitors.

What other stocks do shareholders of TG Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TG Therapeutics investors own include Novavax (NVAX), AK Steel (AKS), Micron Technology (MU), Cara Therapeutics (CARA), Gilead Sciences (GILD), UrtheCast (UR), Verastem (VSTM), BioDelivery Sciences International (BDSI), Sorrento Therapeutics (SRNE) and Corbus Pharmaceuticals (CRBP).

What is TG Therapeutics' stock symbol?

TG Therapeutics trades on the NASDAQ under the ticker symbol "TGTX."

Who are TG Therapeutics' major shareholders?

TG Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.26%), Capital World Investors (2.95%), RA Capital Management L.P. (2.90%), Maverick Capital Ltd. (2.33%), Geode Capital Management LLC (1.63%) and Invesco Ltd. (1.27%). Company insiders that own TG Therapeutics stock include Ra Capital Management, LP, William James Kennedy and Yann Echelard.
View institutional ownership trends for TG Therapeutics.

Which institutional investors are selling TG Therapeutics stock?

TGTX stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Lord Abbett & CO. LLC, Eagle Asset Management Inc., Bridger Management LLC, Panagora Asset Management Inc., Citadel Advisors LLC, Citigroup Inc., and New York State Common Retirement Fund.
View insider buying and selling activity for TG Therapeutics or view top insider-selling stocks.

Which institutional investors are buying TG Therapeutics stock?

TGTX stock was purchased by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Invesco Ltd., 683 Capital Management LLC, BlackRock Inc., Maverick Capital Ltd., Fisher Asset Management LLC, Goldman Sachs Group Inc., and Morgan Stanley.
View insider buying and selling activity for TG Therapeutics or or view top insider-buying stocks.

How do I buy shares of TG Therapeutics?

Shares of TGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TG Therapeutics' stock price today?

One share of TGTX stock can currently be purchased for approximately $15.64.

How much money does TG Therapeutics make?

TG Therapeutics has a market capitalization of $2.21 billion and generates $150 thousand in revenue each year. The biopharmaceutical company earns $-279.38 million in net income (profit) each year or ($2.64) on an earnings per share basis.

How many employees does TG Therapeutics have?

TG Therapeutics employs 272 workers across the globe.

What is TG Therapeutics' official website?

The official website for TG Therapeutics is www.tgtherapeutics.com.

Where are TG Therapeutics' headquarters?

TG Therapeutics is headquartered at 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014.

How can I contact TG Therapeutics?

TG Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company can be reached via phone at (212) 554-4484, via email at [email protected], or via fax at 212-554-4531.